目的 探讨脾氨肽口服液联合依匹斯汀治疗慢性荨麻疹的临床疗效。方法 选取延安大学附属医院2016年5月-2017年5月收治的慢性荨麻疹患者121例，随机分成对照组（60例）和治疗组（61例）。对照组患者口服盐酸依匹斯汀片，2片/次，1次/d；治疗组患者在对照组的基础上口服脾氨肽口服液，10 mL/次，1次/d。两组患者均连续治疗4周。评价两组患者临床疗效，同时比较治疗前后两组患者临床症状积分、血清炎性指标和不良反应。结果 治疗后，对照组的临床总有效率为83.33%，显著低于治疗组的96.72%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者瘙痒、风团数量、风团大小症状积分均明显降低（P<0.05）；且治疗组患者症状积分降低的更明显（P<0.05）。治疗后，两组患者白介素（IL）-4、IL-10和C反应蛋白（CRP）水平显著性降低（P<0.05）；且治疗组患者各指标均明显低于对照组（P<0.05）。治疗期间，治疗组患者不良反应发生率为6.56%，明显低于对照组患者的21.67%，两组比较差异具有统计学意义（P<0.05）。结论 脾氨肽口服液联合依匹斯汀治疗慢性荨麻疹临床疗效显著，同时能够显著改善炎性反应，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Spleen Aminopeptide Oral Solution combined with epinastine in treatment of chronic urticaria. Methods Patients (121 cases) with chronic urticaria in Yan'an University Affiliated Hospital from May 2016 to May 2017 were randomly divided into control (60 cases) and treatment (61 cases) groups. Patients in the control group were po administered with Epinastine Hydrochloride Tablets, 2 tablets/time, once daily. Patients in the treatment group were po administered with Spleen Aminopeptide Oral Solution on the basis of the control group, 10 mL/time, once daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptom scores, serum inflammatory markers and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 83.33%, which was significantly lower than that (96.72%) in the treatment group, and the difference was statistically significant between two groups (P<0.01). After treatment, the symptom scores of pruritus, numbers and size of wheal in two groups were significantly decreased (P<0.05). And these scores in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the serum IL-4, IL-10 and CRP levels in two groups were significantly decreased (P<0.05). And these inflammatory markers in the treatment group were significantly lower than those in the control group (P<0.05). During the treatment, the incidence of adverse reaction in the treatment group was 6.56%, which were significantly lower than 21.67% in the control group, with significant difference between two groups (P<0.05). Conclusion Spleen Aminopeptide Oral Solution combined with epinastine has significant effect in treatment of chronic urticaria, which can significantly improve the inflammatory reaction, which has a certain clinical application value.